NEXT Life Sciences, a Los Angeles, CA-based medical device company raised $1.55M in Seed funding.
Backers were not disclosed.
The company intends to use the funds to support the development and commercialization of Plan A.
Led by L.R. Fox, CEO, NEXT Life Sciences is a medical device company advancing Plan A™, a reversible contraceptive solution for men. Plan A™ utilizes Vasalgel®, a proprietary hydrogel acquired by NEXT. The Plan A™ procedure is similar to that of a no-scalpel vasectomy – except instead of permanently cutting the vas deferens, the hydrogel acts as a flexible filter to block the flow of sperm, preventing pregnancy. Preclinical studies demonstrated rapid restoration of sperm flow after Vasalgel® was dissolved and flushed from the vas deferens.
With the goal to initiate clinical trials by the end of 2023, NEXT has brought together family planning experts to join their Medical Advisory Board, including Dr. Charles Carignan, an experienced CEO and former CMO of Boston Scientific, with extensive contraceptive development experience with Conceptus, WHO, FDA, and USAID.
FinSMEs
05/06/2023